News - Page 142 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022

MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022

Post published:October 26, 2021
Post category:Press Release

Read more about the article MindMed Announces R(-)-MDMA Program to target Social Anxiety Associated with Autism Spectrum Disorder

MindMed Announces R(-)-MDMA Program to target Social Anxiety Associated with Autism Spectrum Disorder

Post published:October 26, 2021
Post category:Press Release

Read more about the article HAVN Life Announces Departure of Rick Brar as Director

HAVN Life Announces Departure of Rick Brar as Director

Post published:October 25, 2021
Post category:Press Release

Read more about the article Delix Therapeutics Announces Appointment of Dr. John Krystal to Scientific & Strategic Advisory Board

Delix Therapeutics Announces Appointment of Dr. John Krystal to Scientific & Strategic Advisory Board

Post published:October 25, 2021
Post category:Press Release

Read more about the article European Patent Grant Strengthens Small Pharma’s Ketamine-Based Patent Portfolio for the Treatment of Depressive Disorders

European Patent Grant Strengthens Small Pharma’s Ketamine-Based Patent Portfolio for the Treatment of Depressive Disorders

Post published:October 25, 2021
Post category:Press Release

Read more about the article MindMed CMO to Chair Digital Biomarkers Summit

MindMed CMO to Chair Digital Biomarkers Summit

Post published:October 25, 2021
Post category:Press Release

Read more about the article Beckley Psytech Announces First Cohort Dosed in Phase 1 Clinical Trial Assessing Safety and Tolerability of Intranasal 5-MeO-DMT

Beckley Psytech Announces First Cohort Dosed in Phase 1 Clinical Trial Assessing Safety and Tolerability of Intranasal 5-MeO-DMT

Post published:October 25, 2021
Post category:Press Release

Read more about the article Psychedelic Bulletin: Small Pharma Secures Fast-Track Designation in UK; Boris Johnson to Consider Rescheduling Psilocybin; COMPASS Reports Psilocybin Group Therapy Data

Psychedelic Bulletin: Small Pharma Secures Fast-Track Designation in UK; Boris Johnson to Consider Rescheduling Psilocybin; COMPASS Reports Psilocybin Group Therapy Data

Post published:October 22, 2021
Post category:Psychedelic Bulletin

Read more about the article Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy for Major Depressive Disorder

Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy for Major Depressive Disorder

Post published:October 21, 2021
Post category:Press Release

Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product

Post published:October 20, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.